Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vericel Corp (NASDAQ:VCEL)

2.65
Delayed Data
As of May 22
 0.00 / 0.00%
Today’s Change
1.96
Today|||52-Week Range
4.55
-11.67%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$86.8M

Company Description

Vericel Corp. engages in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two cell therapy products in the United States of America, Carticel autologous cultured chondrocytes, an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel cultured epidermal autografts, a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Contact Information

Vericel Corp.
64 Sidney Street
Cambridge Massachusetts 02139
P:(617) 588-5555
Investor Relations:

Employees

Shareholders

Individual stakeholders7.02%
Mutual fund holders5.26%
Other institutional36.35%

Top Executives

Dominick C. ColangeloPresident, Chief Executive Officer & Director
Daniel R. OrlandoChief Operating Officer
Gerard J. MichelChief Financial Officer & VP-Corporate Development
David ReckerChief Medical Officer
Jacquelyn Fahey SandellVice President & General Counsel